Prostate Cancer Risk Factors and Evidence-Based Prevention

Prostate cancer is the second most common cancer in men worldwide and the fifth leading cause of male cancer death [^rawla2019]. At the same time, it is one of the most variable cancers in terms of clinical significance — many prostate cancers grow slowly, never cause symptoms, and never require treatment. The challenge for men and clinicians alike is distinguishing between cancers that need intervention and those that can be safely monitored.

Understanding the modifiable risk factors and the evidence-based approach to screening allows for informed rather than reactive decision-making.

Risk factors

Non-modifiable risk factors

Age: The most powerful risk factor. Prostate cancer is rare before 50; incidence increases sharply after 60. Autopsy studies find microscopic prostate cancer in approximately 30% of men in their 50s and 70–80% of men in their 80s — the vast majority of whom died of unrelated causes.

Race and ethnicity: African American men have approximately 1.7× the incidence and 2.1× the mortality of white men. Asian men in Asia have lower rates; rates increase in Asian men who migrate to Western countries, suggesting a diet-environment interaction on a genetic background.

Family history: First-degree relative with prostate cancer approximately doubles risk. Two or more first-degree relatives increases risk 5–11×. BRCA2 mutations are associated with higher-grade disease and 8× increased risk of early-onset prostate cancer.

Modifiable risk factors

Obesity: Higher BMI is associated with higher-grade prostate cancer and worse outcomes, likely via increased insulin and IGF-1 signaling, which promotes tumor proliferation. Obesity is not clearly associated with increased incidence, but is associated with more aggressive disease and greater cancer-specific mortality.

Dietary pattern: High red meat and high-fat dairy consumption are associated with increased prostate cancer risk in epidemiological data. Mediterranean diet patterns (vegetables, fish, olive oil, limited red meat) are associated with lower risk. Ornish et al. (2005) [^ornish2005] demonstrated that intensive lifestyle changes (low-fat plant-based diet, exercise, stress management) significantly slowed PSA progression in men with early prostate cancer.

Physical inactivity: Men with higher physical activity levels consistently show lower prostate cancer mortality, likely through effects on insulin sensitivity, inflammation, and immune function.

Dairy and calcium: High calcium intake (>2000 mg/day) is associated with increased prostate cancer risk in some analyses, possibly via suppression of the active vitamin D form (1,25-dihydroxyvitamin D) that has anti-proliferative effects in prostate tissue. Dietary calcium at normal levels (800–1200 mg/day) is not associated with increased risk.

Sexually transmitted infections: Certain strains of HPV and Trichomonas vaginalis infection show associations with prostate cancer in some studies, though causal mechanisms are not established.

PSA screening: the evidence and the decision

Prostate-specific antigen (PSA) testing is the primary screening tool for prostate cancer. The evidence on population-level PSA screening is more nuanced than simple "get tested" or "don't get tested" guidance.

What PSA is: PSA is a serine protease produced by prostate epithelial cells. It is not a cancer-specific marker — PSA rises with BPH, prostatitis, and after procedures, as well as cancer. A normal PSA is typically <4.0 ng/mL, though age-adjusted ranges exist (younger men with PSA >2.5 warrant attention; older men with borderline 4–10 range require judgment).

The screening trials: Two major RCTs (ERSPC in Europe and PLCO in the US) produced different results. ERSPC showed ~20% reduction in prostate cancer mortality with PSA screening at 13 years; PLCO showed no benefit. The difference is largely attributed to high rates of opportunistic PSA testing in the "unscreened" arm of PLCO, contaminating the control group [^martin2012].

The overdiagnosis issue: PSA screening detects more cancer — including low-grade, slow-growing cancers that would never cause harm. This leads to treatment of cancers that didn't need treatment, with associated side effects (incontinence, erectile dysfunction from radiation or surgery). Estimates suggest that 20–50% of PSA-detected cancers are overdiagnosed.

The current consensus (2020s): Shared decision-making is preferred over uniform screening mandates. Men aged 50–70 at average risk should discuss PSA testing with their physician, understanding both the potential mortality benefit and the overdiagnosis risk. Men at higher risk (Black men, family history, BRCA2 carriers) should begin discussions at age 40–45.

Active surveillance is now the standard approach for low-risk (Gleason 6) localized prostate cancer, precisely because of the overdiagnosis-overtreatment problem. Klotz (2010) [^klotz2012] established that properly selected low-risk cancers can be monitored safely with serial PSA, imaging, and biopsy without immediate intervention.

Prevention: what is actionable

Exercise: The most consistently supported modifiable factor. 150+ minutes per week of moderate-intensity aerobic activity and resistance training reduce cancer mortality risk broadly and improve outcomes in men with prostate cancer.

Body weight: Maintaining healthy BMI reduces risk of aggressive disease. Weight reduction in obese men reduces insulin and IGF-1 levels within months.

Dietary shift: Reducing red meat and high-fat dairy; increasing vegetables, legumes, and fish. The mechanism is likely multi-factorial (inflammation, hormonal, IGF-1). Neither a single "anti-cancer food" nor complete dietary transformation is necessary — a directional shift toward plant-forward eating has consistent epidemiological support.

Tomatoes and lycopene: Lycopene is the most studied prostate-specific phytonutrient. Pernar et al. (2018) [^pernar2018] review the mechanistic and epidemiological evidence. Cooked tomatoes (sauce, paste) deliver more bioavailable lycopene than raw tomatoes. Consuming tomato products 2+ times per week is a low-cost, no-harm nutritional practice.

Vitamin D: Active vitamin D has anti-proliferative effects in prostate tissue. Maintaining adequate serum vitamin D (40–60 ng/mL) is recommended for male health broadly; its potential prostate-specific benefit is a secondary reason.

5-ARI medications as chemoprevention: Finasteride and dutasteride reduce prostate cancer incidence by approximately 25% in clinical trials (PCPT and REDUCE trials). However, in these trials, the cancer that did occur in the treatment arms was more often high-grade. The FDA did not approve either drug for cancer prevention as a result. This remains an area of clinical judgment, not routine recommendation.

Practical risk stratification

For most men, the practical action steps are:

• Discuss PSA testing at age 50 (earlier at 40–45 if Black or family history of prostate cancer or BRCA2)
• Maintain exercise and healthy weight
• Directional dietary improvements (reduce processed meat, increase vegetables and fish)
• Adequate vitamin D status
• Know your family history and communicate it to your physician

Prostate cancer fear should not drive avoidance of prostate health discussion. The same medical engagement that enables early detection also enables informed surveillance decisions that avoid unnecessary treatment.